1.49 USD
↘ 0.04 (2.30%)LIVE (AS OF 02:00 PM EST)
Inhibikase Therapeutics, Inc. Common Stock (IKT) trades at $1.49 per share. Technicals currently rate "Strong Sell" while our fundamental analysis reads "Neutral". This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics suggest IKT is trading at a discount to its peers, earning an "Attractively Valued" rating.
Technical & fundamental data as of Nov 13, 2026.